Bayer presents new Levitra study

Bayer Schering Pharma has presented the results of a new study of a treatment of Levira (vardenafil HCI) at the 23rd annual congress of the European Association of Urology.

The trials showed that the treatment for erectile dysfunction works well in men with dyslipidemia, with Levitra significantly improving the ability of men with high cholesterol and erectile dysfunction to achieve and maintain an erection for intercourse.

Erectile dysfunction and testosterone deficiency can share the same root causes, including cardiovascular disease, obesity and dyslipidemia.

Additionally at the conference, the firm presented new data from the European Testogel study, which showed that administration of Testogel may improve cardiovascular and metabolic conditions in men with hypogonadism.

Ian Eardley, consultant urologist and honorary senior lecturer at St James University Hospital in Leeds, said: “Erectile dysfunction is very often associated with high cholesterol.

“Many physicians are not treating erectile dysfunction, a life-changing condition.”

He added that the study provides evidence that Levitra can successfully treat erectile dysfunction, even in men with serious underlying conditions, a factor that applies to nearly 70 per cent of men suffering from erectile dysfunction.

In September 2006, Bayer published the results of a study that showed that Levitra is “at least as good as Viagra” as a treatment for erectile dysfunction.